Pemetrexed DisodiumThird Party Manufacturing in India

Pemetrexed Disodium works by inhibiting three critical folate-dependent enzymes involved in purine and pyrimidine synthesis: thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT). As a multi-targeted antifolate metabolic inhibitor, it disrupts the synthesis of nucleotides required for DNA and RNA replication. This inhibition halts cell division and induces cell cycle arrest and apoptosis in rapidly proliferating cancer cells, effectively slowing down tumor growth.

Therapeutic Uses

Pemetrexed Disodium is indicated for the treatment of:

• Malignant Pleural Mesothelioma: Used in combination with cisplatin for patients whose disease is unresectable or who are not candidates for curative surgery.
• Non-Squamous Non-Small Cell Lung Cancer (NSCLC): Used as monotherapy or combination therapy for the treatment of locally advanced or metastatic non-squamous NSCLC.

Why Manufacturers Choose Pemetrexed Disodium

Pemetrexed Disodium is a core chemotherapy drug in lung cancer regimens, maintaining a steady demand in oncology centers worldwide. Its synthesis and formulation as a sterile lyophilized powder (100mg and 500mg) require high-containment oncology injectable manufacturing blocks to prevent cross-contamination.

By choosing Pemetrexed Disodium third party manufacturing in India from WHO-GMP certified facilities, global distributors can access premium, cost-effective oncology products. The availability of high-quality active pharmaceutical ingredients (APIs) and specialized manufacturing in India supports competitive contract manufacturing pricing and robust supply chains for export and domestic markets.